# AxoGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axogen

- Industry: Medical Devices & Equipment
- Headquarters: Alachua, US
- Website: www.axogeninc.com
- Total disclosed funding: $22M
- Latest round: Series D (Jan 7, 2010)
- Investors on record: 4

## About

AxoGen focuses on surgical solutions for peripheral nerve repair, providing innovative products that restore function and feeling to damaged nerves, primarily targeting healthcare providers in various surgical fields.AxoGen develops surgical solutions for peripheral nerve repair, focusing on biological products that aid in nerve regeneration. Founded in the US, the company is headquartered in Alachua, Florida and has received funding through several rounds. In August 2015, Essex Woodlands invested USD 17.1 mn in AxoGen. The company has completed a total of 8 deals, with its latest funding round being a PIPE, raising a total of USD 17.1 mn.AxoGen specializes in surgical solutions for peripheral nerve repair, primarily offering products designed to restore feeling and functionality to damaged peripheral nerves. Their flagship product, the Avance® Nerve Graft, serves as a biological solution for nerve repair, allowing for the regeneration of nerves after injury. The company’s offerings are employed by a range of medical professionals, including hand surgeons, reconstructive plastic surgeons, and oral and maxillofacial surgeons, in various surgical procedures aimed at addressing nerve injuries. The primary end users of Axogen's products are patients suffering from nerve damage due to traumatic events, such as accidents or surgeries, who seek to regain mobility and sensory function. Axogen's products are marketed and sold primarily in North America and select international markets where there is a demand for advanced nerve repair solutions.In the most recent fiscal year 2024, AxoGen reported a revenue of USD 187.34 mn and an EBITDA of USD 4.28 mn. The company generates revenue through a direct sales model, supplying its nerve repair products to healthcare providers and surgical specialists. Transactions typically occur through orders placed by hospitals and surgical centers, where AxoGen's products are utilized during nerve repair surgeries.AxoGen plans to leverage its recent PIPE funding of USD 17.1 mn to enhance its product development and expand its market presence. The company is focused on introducing new products aimed at improving peripheral nerve repair solutions. As part of its growth strategy, AxoGen is targeting expansion into additional international markets by 2026, aiming to increase the accessibility of its nerve repair technologies. The funding will support these initiatives, further solidifying AxoGen's position in the nerve repair sector.

## Funding rounds

- Series D, Jan 7, 2010, $3.4M — Accuitive Medical Ventures
- Series C, Nov 5, 2007, $12M — Cardinal Partners, De Novo Ventures, Accuitive Medical Ventures, Springboard Capital
- Series B, Mar 13, 2006, $7M — Cardinal Partners, De Novo Ventures, Accuitive Medical Ventures, Springboard Capital

## Investors

- Cardinal Partners (https://capitalatlas.ai/funds/cardinal-partners) — Series B, Series C
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series B, Series C
- Accuitive Medical Ventures (https://capitalatlas.ai/funds/accuitive-medical-ventures) — Series B, Series C, Series D
- Springboard Capital (https://capitalatlas.ai/funds/springboard-capital) — Series B, Series C